Sun Pharma Advanced Research Co

Sun Pharma Advanced Research Co EBITDA per Share

The EBITDA per Share of Sun Pharma Advanced Research Co (SPARC.NS) as of Oct 15, 2026 is 48.95 INR. In the previous year, EBITDA per Share was -9.90 INR — a change of -594.34% (higher).

EBITDA per Share

48.95INR

YoY

-594.34%

Last updated:

EBITDA per Share of Sun Pharma Advanced Research Co is 2026 48.95 INR. EBITDA per Share of Sun Pharma Advanced Research Co was 2025 -9.90 INR. It decreases by -594.34% higher compared to the previous year.

The Sun Pharma Advanced Research Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-5.52 INR
Jan 1, 2020
-11.66 INR
Jan 1, 2021
-4.91 INR
Jan 1, 2022
-6.20 INR
Jan 1, 2023
-6.53 INR
Jan 1, 2024
-12.29 INR
Jan 1, 2025
-9.90 INR
Jan 1, 2026
48.95 INR
The Sun Pharma Advanced Research Co EBITDA per Share history
YEAREBITDA per ShareYoY
48.95INR-594.34%
-9.90INR-19.46%
-12.29INR+88.31%
-6.53INR+5.24%
-6.20INR+26.40%
-4.91INR-57.89%
-11.66INR+111.10%
-5.52INR-42.25%
-9.56INR+92.90%
-4.96INR+95.58%
-2.53INR+73.20%
-1.46INR-203.06%
1.42INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sun Pharma Advanced Research Co Stock analysis

What does Sun Pharma Advanced Research Co do? Sun Pharma Advanced Research Co Ltd, listed on the National Stock Exchange of India with ticker SPARC.NS and ISIN INE232I01014, is a pharmaceutical company headquartered in Mumbai, India. The company operates within the healthcare sector, specifically in the pharmaceutical industry, and employs 407 full-time staff. It completed its initial public offering on July 18, 2007. Sun Pharma Advanced Research focuses on research and development of pharmaceutical products targeting unmet medical needs, particularly in the fields of oncology, neurodegeneration, and immunology. The company develops New Chemical Entities (NCEs), New Biological Entities, and reformulated products. Specific NCEs mentioned include SCC-138, SCO-088, SCO-120, and SCD-044. It also utilizes Novel Drug Delivery Systems (NDDS), such as Wrap Matrix Technology for controlled-release tablets, Lipexelle technology for ophthalmic formulations, and TearAct Technology for eye drops. Products developed using these technologies include Elepsia XR, which employs Wrap Matrix Technology, and Xelpros, a BAK-free latanoprost eye drop developed with Lipexelle technology and commercialized in the United States by a partner. Additionally, the company has created PDP-716 eye drops for glaucoma treatment using TearAct Technology. The company's website is https://www.sparc.life/. Sun Pharma Advanced Research Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sun Pharma Advanced Research Co stock

EBITDA per Share of Sun Pharma Advanced Research Co is 48.95 INR in 2026.

EBITDA per Share of Sun Pharma Advanced Research Co changed from -9.90 INR to 48.95 INR, representing a -594.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Sun Pharma Advanced Research Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Sun Pharma Advanced Research Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Sun Pharma Advanced Research Co